Pharmafile Logo

News and Press Releases

FGK Clinical Research GmbH Acquires Clinicology Ltd, Expanding Territorial Footprint in Europe

22 February 2024 -- Munich, Germany -- FGK Clinical Research GmbH, a European-based full-service provider of clinical research services, is thrilled to announce the successful acquisition of Clinicology Ltd, a...

Category: Clinical Trials
Posted: February 22, 2024

FGK Clinical Research
info@fgk-cro.com
Heimeranstrasse 35 80339 Munich, Germany

Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early

7 February 2024 -- Birmingham, UK -- NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry...

Category: Biotechnology
Posted: February 7, 2024

Informed Genomics
info@informedgenomics.com
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham, B32 1AF

First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial

Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...

Category: Drug Discovery
Posted: February 7, 2024

Peptomyc
lsoucek@peptomyc.com
C/ Natzaret, 115-117 Barcelona, Spain, 08035

Greenphire Announces Acquisition of Clincierge to Enhance Clinical Trial Support Services

Addition enables sponsors to solve the number one clinical trial participant obstacle – transportation, with a single industry-leading solution 1 February 2024 -- Pennsylvania, US -- Greenphire, a leading innovator in...

Category: Clinical Trials
Posted: February 1, 2024

Greenphire
1018 W. 9th Avenue, Suite 200 King of Prussia, PA 19406

Calypso Enters into Agreement to Be Acquired by Novartis

Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmune indications The acquisition of Calypso gives Novartis...

Category: Biotechnology
Posted: January 8, 2024

Calypso Biotech
Gustav Mahlerplein 102 1082 MA Amsterdam The Netherlands

Landmark Phase 3 MARIPOSA Study Shows RYBREVANT▼(amivantamab) Plus Lazertinib Resulted in 30% Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated NSCLC

Early data show an overall survival trend favoring the combination of amivantamab and lazertinib compared to osimertinib; consistent results seen in patients with and without brain metastases Late-breaking results from...

Category: Clinical Trials
Posted: October 24, 2023

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy

Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...

Category: Clinical Trials
Posted: October 23, 2023

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

European Commission Approves ADCETRIS (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD  

· Approval Based on Updated Positive Overall Survival Results from the phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma  · First Significant Improvement in Overall Survival in Two Decades...

Category: Pharmaceutical
Posted: October 23, 2023

Takeda Pharmaceutical Company
61 Aldwych, London, WC2B 4AE, UK

MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland

Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...

Category: Pharmaceutical
Posted: October 9, 2023

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France